研究单位：[1]BeyondSpring Pharmaceuticals Inc.[2]Cancer Center of Guangzhou Medical University Guangzhou, Guangdong, China[3]Cancer Center of Guangzhou Medical University Breast Oncology Guangzhou, Guangzhou, China, 510000[4]Harbin Medical University Cancer Hospital Harbin, Harbin, China, 150000[5]Fourth Hospital of Hebei Medical University Breast cancer department Shijiazhuang, Hebei, China, 500000河北医科大学第四医院[6]China-Japan Union Hospital of Jilin University Tumor department of Hematology Changchun, Jilin, China, 130000[7]Liaoning Cancer Hospital & Institute Shenyang, Shenyang, China, 110000[8]Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department Dnepropetrovsk, Ukraine, 49102[9]Prykarpatskiy Regional Oncological Center Ivano-Frankivs'k, Ukraine[10]Regional Clinical Oncology Center Kharkiv, Ukraine[11]V.T. Zaycev Institute Kharkiv, Ukraine[12]Public Institution Kryvyi Rih Oncology Center Krivoy Bereg, Ukraine, 50048[13]Kirovograd Regional Oncological Center Kropyvnytskyi, Ukraine, 25011[14]Hemotherapy Department Kyiv, Ukraine[15]Kyiv City Clinical Oncological Center Kyiv, Ukraine[16]Lviv State Oncological Regional Lviv, Ukraine[17]Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho Odessa, Ukraine, 65025[18]Zakarpattia Regional Clinical Oncology Center Uzhgorod, Ukraine[19]Vinnytsya Regional Clinical Oncology Dispensary Vinnytsia, Ukraine[20]Zaporizhia Regional Clinical Oncology Dispensary Zaporizhzhya, Ukraine[21]No. 1 Banshandong Road Hangzhou, Gongshu District, China
The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with:
Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim
Severe neutropenia is an absolute neutrophil count (ANC) <0.5 × 10^9/L.
Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.
